Ranolazine
Ranolazine is an antianginal, a medicine taken by mouth to treat angina. The US label read, for generic ranolazine extended-release tablets, lists the treatment of chronic angina and says the tablets may be used with several other medicine groups for the heart and blood vessels. The label says the mechanism of its antianginal effects has not been determined.
- Drug
- In this atlas
Overview
Technical summary
RxNorm ingredient 35829; UNII A6IEZ5M406. MeSH descriptor D000069458 is Ranolazine. RxClass lists the FDA established pharmacologic class Anti-anginal; the atlas has no page for that class, so the record has no class parent. The label read is the Glenmark Pharmaceuticals Inc., USA generic extended-release tablet label, application ANDA211082, effective 2026-01-23 in openFDA. The plan row listed set id 00979fb3 (Viona Pharmaceuticals Inc, ANDA210188) beside the application number ANDA211082; the Glenmark label for ANDA211082 is used. An openFDA brand-name search for Ranexa returned no record on 2026-11-18, and the Aspruzyo Sprinkle record (NDA216018) and other generic and repackager labels were not read. This page records the label indication, the list of medicines the label says it may be used with, and the mechanism sentences only: no trial result and no dose is given.
About this drug
- Level
- Substance
- Mechanism
- The label says the mechanism of ranolazine's antianginal effects has not been determined. At therapeutic levels it can inhibit the cardiac late sodium current, but the label says the relationship of this inhibition to angina symptoms is uncertain.
Claims and evidence
Context People with chronic angina, as described in the US label of generic ranolazine extended-release tablets
- Recipient
- Recipient not specified
- Population
- Patients with chronic angina, as the indications section of the label states. The label passages read do not state an age range.
- Care setting
- Prescription medicine, as described in the US label
- Geography
- United States (label of the US Food and Drug Administration)
- Life stage
- Not stated in the label passages read
- Gestational age
- Not reported
- Postnatal age
- Not reported
- Follow-up
- Not applicable (label statement)
Eligibility: 1 inclusion criterion; exclusion criteria not stated
- Included
- Patients with chronic angina
- Excluded
- None stated
The US label of ranolazine extended-release tablets (Glenmark Pharmaceuticals Inc., USA, application ANDA211082; the version dated 2026-01-23 in openFDA) lists the treatment of chronic angina and says the tablets may be used with beta-blockers, nitrates, calcium channel blockers, anti-platelet therapy, lipid-lowering therapy, ACE inhibitors, and angiotensin receptor blockers. The label also says the mechanism of ranolazine's antianginal effects has not been determined. It says ranolazine can inhibit the cardiac late sodium current at therapeutic levels, and that the relationship of this inhibition to angina symptoms is uncertain.
Applies to Recipient not specified People with chronic angina, as described in the US label of generic ranolazine extended-release tablets
- Certainty method
- Not assessed
- Limitations
- This claim records what one US label says the medicine is indicated for and how it describes the medicine. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. The label is for a generic product; the brand label and other ranolazine products were not read. The list of medicines that may be used with it is the label's own statement and is not a recommendation of this atlas. The label passages read state no age range except where the claim says adults. Contraindications, warnings, interactions, use in pregnancy and in children, and dosing were not recorded. Labels change, and openFDA lists other versions with different dates. openFDA's own disclaimer says not to rely on it for decisions about medical care.
- Last checked
- 2026-11-18
- Next evidence check due
- Not scheduled
Sources and citations (4)
-
- Locator
- results[0].openfda.application_number[0]
- How it applies
- Application number of the label read.
- Retrieved
- Source effective date
- 2026-01-23
- Source state
- Current
- Version fingerprint
b4f132e1c3f78d1f5437ed9faf41612ec62a96e7a270aeeefe960cb96fd683fb- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-18, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
-
- Locator
- results[0].effective_time
- How it applies
- Effective date of the label text read.
- Retrieved
- Source effective date
- 2026-01-23
- Source state
- Current
- Version fingerprint
b4f132e1c3f78d1f5437ed9faf41612ec62a96e7a270aeeefe960cb96fd683fb- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-18, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
-
- Locator
- results[0].indications_and_usage[0]
- How it applies
- Label passage quoted in the research quote table (RAN-LB-04, RAN-LB-05).
- Retrieved
- Source effective date
- 2026-01-23
- Source state
- Current
- Version fingerprint
b4f132e1c3f78d1f5437ed9faf41612ec62a96e7a270aeeefe960cb96fd683fb- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-18, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
-
- Locator
- results[0].mechanism_of_action[0]
- How it applies
- Label passage quoted in the research quote table (RAN-LB-06, RAN-LB-07, RAN-LB-08).
- Retrieved
- Source effective date
- 2026-01-23
- Source state
- Current
- Version fingerprint
b4f132e1c3f78d1f5437ed9faf41612ec62a96e7a270aeeefe960cb96fd683fb- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-18, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
Clinical links
Each link reports what one cited claim says about one population. "Evaluated for" means studied, not shown to work. These links do not show that anything is effective or right for you.
-
Claim, not a settled fact FDA label lists the treatment of chronic angina as the indication: Angina pectoris
Applies to Recipient not specified People with chronic angina, as described in the US label of generic ranolazine extended-release tablets
The US label of ranolazine extended-release tablets (Glenmark Pharmaceuticals Inc., USA, application ANDA211082; the version dated 2026-01-23 in openFDA) lists the treatment of chronic angina and says the tablets may be used with beta-blockers, nitrates, calcium channel blockers, anti-platelet therapy, lipid-lowering therapy, ACE inhibitors, and angiotensin receptor blockers. The label also says the mechanism of ranolazine's antianginal effects has not been determined. It says ranolazine can inhibit the cardiac late sodium current at therapeutic levels, and that the relationship of this inhibition to angina symptoms is uncertain.Limitations. This claim records what one US label says the medicine is indicated for and how it describes the medicine. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. The label is for a generic product; the brand label and other ranolazine products were not read. The list of medicines that may be used with it is the label's own statement and is not a recommendation of this atlas. The label passages read state no age range except where the claim says adults. Contraindications, warnings, interactions, use in pregnancy and in children, and dosing were not recorded. Labels change, and openFDA lists other versions with different dates. openFDA's own disclaimer says not to rely on it for decisions about medical care.
Record details
- Record id
cardio:ranolazine- Content hash
843798e30d762b96231c9045842b3ed4805308815ee63230a29310fa0807a291